A Geographic Disparities Analysis Between Standard of Care and Clinical Trial CAR ‐T Patients in Kansas
Cancer Medicine · 2026-05 · 15 (5)
DOI: 10.1002/cam4.71974 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 22.05.2026. Verfasst von Sam Pepper und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics & Data Science, The University of Kansas Medical Center, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Healthcare Disparities, Immunotherapy, Adoptive, Standard of Care, Health Services Accessibility. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Cancer Center Support Grant.
Abstract (Originalsprache)
Background
This study compares demographics and geographic factors associated with access to chimeric antigen receptor (CAR)‐T cell therapy for B‐cell malignancies or multiple myeloma: individuals in clinical trials at the University of Kansas Cancer Center (KUCC) and those receiving standard‐of‐care (SOC) CAR‐T at the University of Kansas Health System (TUKHS).
Methods
Data were collected from electronic medical records and the KUCC Clinical Trial Management System. We evaluated differences in CAR‐T access across race, gender, age, rurality, and HPSA status. SOC patients received FDA‐approved CAR‐T between May 2021 and May 2023; clinical trial patients received investigational CAR‐T between January 2015 and February 2023.
Results
Most patients (80%) were from urban areas; 54.1% lived within 50 miles of the University of Kansas Medical Center (KUMC). The cohort was 58.4% male, 86.7% white, 60.4% aged 19–64, and 57% lived outside a Health Professional Shortage Area (HPSA). Rural patients made up 20% of both cohorts. No significant demographic differences were observed between clinical trial and SOC recipients. However, rural residence was significantly associated with age 65 or older (OR = 1.80), white race, HPSA status, and living more than 50 miles from KUMC (OR = 27.01). HPSA status was also associated with greater odds of living beyond the 50‐mile radius (OR = 2.29).
Conclusions
Findings highlight important geographic disparities in CAR‐T access. Targeted outreach to rural and HPSA‐designated communities may improve equity and ensure broader access to advanced therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics & Data Science, The University of Kansas Medical Center, Kansas City, Kansas, USA.
- University of Kansas Cancer Center, Kansas City, Kansas, USA.
- University of Kansas Medical Center, Division of Hematologic Malignancies & Cellular Therapeutics, Kansas City, Kansas, USA.
- Department of Internal Medicine, University of Kansas Medical Center, Kansas, USA.
Förderung
- NCI NIH HHS
- Cancer Center Support Grant
Zitieren
APA
Pepper, S., Rashid, A., Tabak, C., Ratnayake, I., Rahman, M. M., Talukder, M. R. I., McGuirk, M., Rippee, O., McGuirk, J., Hoffmann, M., Sung, A. D., Ahmed, N., & Mudaranthakam, D. P. (2026). A Geographic Disparities Analysis Between Standard of Care and Clinical Trial CAR ‐T Patients in Kansas. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71974
Vancouver
Pepper S, Rashid A, Tabak C, Ratnayake I, Rahman MM, Talukder MRI, et al. A Geographic Disparities Analysis Between Standard of Care and Clinical Trial CAR ‐T Patients in Kansas. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71974
BibTeX
@article{Pepper2026,
author = {Pepper, Sam and Rashid, Aliya and Tabak, Carine and Ratnayake, Isuru and Rahman, Mohammod Mahmudur and Talukder, Md Robiul Islam and McGuirk, Matthew and Rippee, Olivia and McGuirk, Joseph and Hoffmann, Marc and Sung, Anthony D and Ahmed, Nausheen and Mudaranthakam, Dinesh Pal},
title = {A Geographic Disparities Analysis Between Standard of Care and Clinical Trial CAR ‐T Patients in Kansas},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cam4.71974}
}
EUVIMED